Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference

Rhea-AI Summary

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) announced its participation in the 31st Annual Oppenheimer Healthcare Conference on March 16, 2021, at 3:10 PM Eastern Time. The conference will be held virtually from March 16 to 18, with a live webcast available for following the presentation. Satsuma is focused on developing STS101, a novel treatment for acute migraine, utilizing a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE) that simplifies self-administration. The company aims to enhance the clinical effectiveness of DHE while addressing limitations of existing treatments.

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present a corporate overview at the 31^st Annual Oppenheimer Healthcare Conference on March 16, 2021 at 3:10 PM Eastern Time. The conference will be held virtually with participants joining remotely from March 16^th to the 18^th.

A webcast of the presentation can be followed live online via the link below: https://wsw.com/webcast/oppenheimer9/stsa/2746007 or please visit the “Events and Presentations” page within the “Investors” section of the Satsuma Pharmaceuticals website at www.satsumarx.com.

If you are interested in arranging a one-on-one meeting, please contact your Oppenheimer & Co. Inc. representative or contact Corey Davis at LifeSci Advisors.

About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is in Phase 3 development and specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.

INVESTOR AND CORPORATE CONTACTS:         

Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com

FAQ

What is the date of Satsuma Pharmaceuticals' presentation at the Oppenheimer Healthcare Conference?

Satsuma Pharmaceuticals will present on March 16, 2021, at 3:10 PM Eastern Time.

How can I watch the Satsuma Pharmaceuticals presentation live?

You can watch the presentation live via the webcast link provided in their announcement.

What is STS101 developed by Satsuma Pharmaceuticals?

STS101 is a novel therapeutic candidate for the acute treatment of migraine, utilizing a proprietary dry-powder formulation of dihydroergotamine mesylate.

What are the advantages of STS101 over current migraine treatments?

STS101 is designed to offer the clinical benefits of DHE while overcoming the limitations of existing injectable and nasal spray products.

Where is Satsuma Pharmaceuticals headquartered?

Satsuma Pharmaceuticals is headquartered in South San Francisco, California.